Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787302 · ClinicalTrials.gov registry record · Phase 1
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04787302 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT04787302, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
Interventions
- DRUG CVL-231
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04787302
The ClinicalTrials.gov registry entry for NCT04787302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVL-231 is the first listed.
NCT04787302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04787302 about?
NCT04787302 is a clinical study titled "PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing". PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
What is the current status of trial NCT04787302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-06-01. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT04787302?
The interventions under investigation include: CVL-231 (DRUG).
Who is sponsoring clinical trial NCT04787302?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.